An antagonist at α1- and β-adrenergic receptors. Displays antioxidant and antiapoptotic effects in vivo.
Product Details
| Alternative Name: | 1-(9H-Carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol |
| |
| Formula: | C24H26N2O4 |
| |
| MW: | 406.5 |
| |
| CAS: | 72956-09-3 |
| |
| Purity: | ≥98% (UHPLC) |
| |
| Appearance: | White to off-white crystalline powder |
| |
| Solubility: | Soluble in DMSO (>25mg/ml) or 100% ethanol (10mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | +4°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients: G. Jonsson, et al.; J. Cardiovasc. Pharmacol.
49, 27 (2007),
Abstract;
Effect of alpha1-adrenergic receptors in cardiac pathophysiology: R. Shannon & M. Chaudhry; Am. Heart J.
152, 842 (2006),
Abstract;
Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors: T.A. Koshimizu, et al.; Cardiovasc. Res.
63, 662 (2004),
Abstract;
Effects of carvedilol on oxidative stress in human endothelial cells and healthy volunteers: S.A. Fahlbusch, et al.; Eur. J. Clin. Pharmacol.
60, 83 (2004),
Abstract;
Importance of antioxidant and antiapoptotic effects of beta-receptor blockers in heart failure therapy: K. Kawai, et al.; Am. J. Physiol. Heart Circ. Physiol.
287, H1003 (2004),
Abstract;
